|
|
|
| Research progress on molecular biomarkers of endometrial atypical hyperplasia |
| LYU Mingyi1 SUN Huiting2 LIU Huijun2 WANG Linxiao3 LIU Sufen4#br# |
1.Graduate School, Dalian Medical University, Liaoning Province, Dalian 116044, China;
2.Reproductive Center, the Affiliated Changzhou Second People’s Hospital, Nanjing Medical University, Jiangsu Province, Changzhou 213000, China; 3.Central Laboratory, the Affiliated Changzhou Second People’s Hospital, Nanjing Medical University, Jiangsu Province, Changzhou 213000, China; 4.Department of Gynecology, the Affiliated Changzhou Second People’s Hospital, Nanjing Medical University, Jiangsu Province, Changzhou 213000, China |
|
|
|
Abstract Endometrium atypical hyperplasia (EAH) is the precancerous lesion of endometrial cancer, its incidence rate is increasing year by year. With the continuous updating of the screening methods, the detection methods of EAH lesions are constantly updated. At present, the most commonly used detection method in clinic is histopathological examination, but there is no specific molecular biomarker. This paper reviews the recent advances in molecular biomarkers for diagnosis of EAH, such as steroid hormone receptors (estrogen receptors, progesterone receptors), proto-oncogenes and tumor suppressor genes (B-lymphocytoma-2, phosphatase and tensin homologues, P53, and AT-rich domain protein 1A), microRNA and their research status was analyzed.
|
|
|
|
|
|
[1] Wang Y，Yu M，Yang JX，et al. Genomic Comparison of Endometrioid Endometrial Carcinoma and Its Precancerous Lesions in Chinese Patients by High-Depth Next Generation Sequencing [J]. Front Oncol，2019，9：123.
[2] Cornel K，Wouters K，Van de Vijver KK，et al. Gene Promoter Methylation in Endometrial Carcinogenesis [J]. Pathol Oncol Res，2019，25（2）：659-667.
[3] Depciuch J，Barnas E，Skret-Magierlo J，et al. Spectroscopic evaluation of carcinogenesis in endometrial cancer [J]. Sci Rep，2021，11（1）：9079.
[4] Sanderson PA，Critchley HO，Williams AR，et al. New concepts for an old problem：the diagnosis of endometrial hyperplasia [J]. Hum Reprod Update，2017，23（2）：232-254.
[5] Zhao S，Li W，Yu W，et al. Exosomal miR-21 from tubular cells contributes to renal fibrosis by activating fibroblasts via targeting PTEN in obstructed kidneys [J]. Theranostics，2021，11（18）：8660-8673.
[6] 姜芳，许敏，郑锡铭.强直性脊柱炎患者外周血miR-146a、miR-155、miR-181a、miR-223的表达分析[J].实验与检验医学，2018，36（5）：766-769，772.
[7] 孟轶婷，马东林，李莉，等.PAX-2和PTEN在子宫内膜病变中的表达及其与子宫内膜上皮内瘤变的相关性[J].肿瘤研究与临床，2017，29（1）：27-31.
[8] Chaurasiya S，Wu W，Strom AM，et al. Estrogen receptor beta regulates AKT activity through up-regulation of INPP4B and inhibits migration of prostate cancer cell line PC-3 [J]. Proc Natl Acad Sci U S A，2020，117（42）：26347-26355.
[9] Karim H，Kim SH，Lapato AS，et al. Increase in chemokine CXCL1 by ERbeta ligand treatment is a key mediator in promoting axon myelination [J]. Proc Natl Acad Sci U S A，2018，115（24）：6291-6296.
[10] Yuan B，Clark CA，Wu B，et al. Estrogen receptor beta signaling in CD8+ T cells boosts T cell receptor activation and antitumor immunity through a phosphotyrosine switch [J]. J Immunother Cancer，2021，9（1）：e001932.
[11] Werner LR，Gibson KA，Goodman ML，et al. Progesterone promotes immunomodulation and tumor development in the murine mammary gland [J]. J Immunother Cancer，2021，9（5）：e001710.
[12] Latgé G，Poulet C，Bours V，et al. Natural Antisense Transcripts：Molecular Mechanisms and Implications in Breast Cancers [J]. Int J Mol Sci，2018，19（1）：123.
[13] Sun Y，Lu D，Yin Y，et al. PTEN alpha functions as an immune suppressor and promotes immune resistance in PTEN-mutant cancer [J]. Nat Commun，2021，12（1）：5147.
[14] Hutt S，Tailor A，Ellis P，et al. The role of biomarkers in endometrial cancer and hyperplasia：a literature review [J]. Acta Oncol，2019，58（3）：342-352.
[15] Levine A. Jp53：800 million years of evolution and 40 years of discovery [J]. Nat Rev Cancer，2020，20（8）：471-480.
[16] Kastenhuber ER，Lowe SW. Putting p53 in Context [J]. Cell，2017，170（6）：1062-1078.
[17] Liu J，Zhang C，Hu W，et al. Tumor suppressor p53 and metabolism [J]. J Mol Cell Biol，2019，11（4）：284-292.
[18] Ubby I，Krueger C，Rosato R，et al. Cancer therapeutic targeting using mutant-p53-specific siRNAs [J]. Oncogene，2019，38（18）：3415-3427.
[19] Hernandez BL，El-Deiry WS. Tumor suppressor p53：Biology，signaling pathways，and therapeutic targeting [J]. Biochim Biophys Acta Rev Cancer，2021，1876（1）：188556.
[20] Muys BR，Anastasakis DG，Claypool D，et al. The p53-induced RNA-binding protein ZMAT3 is a splicing regulator that inhibits the splicing of oncogenic CD44 variants in colorectal carcinoma [J]. Genes Dev，2021，35（1/2）：102-116.
[21] Raffone A，Travaglino A，Saccone G，et al. Diagnostic and prognostic value of ARID1A in endometrial hyperplasia：a novel marker of occult cancer [J]. APMIS，2019， 127（9）：597-606.
[22] Tomihara H，Carbone F，Perelli L，et al. Loss of ARID1A Promotes Epithelial-Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress [J]. Cancer Res，2021，81（2）：332-343.
[23] Travaglino A，Raffone A，Saccone G，et al. Loss of B-cell lymphoma 2 immunohistochemical expression in endometrial hyperplasia：A specific marker of precancer and novel indication for treatment：A systematic review and meta-analysis [J]. Acta Obstet Gynecol Scand，2018， 97（12）：1415-1426.
[24] Orbo A，Arnes M，Lysa LM，et al. HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia [J]. Br J Cancer，2016，115（6）：725-730.
[25] Giglio S，Annibali V，Cirombella R，et al. miRNAs as Candidate Biomarker for the Accurate Detection of Atypical Endometrial Hyperplasia/Endometrial Intraepithelial Neoplasia [J]. Front Oncol，2019，9：526.
[26] Yamada Y，Nishikawa R，Kato M，et al. Regulation of HMGB3 by antitumor miR-205-5p inhibits cancer cell aggressiveness and is involved in prostate cancer pathogenesis [J]. J Hum Genet，2018，63（2）：195-205.
[27] Mo C，Huang B，Zhuang J，et al. LncRNA nuclear-enriched abundant transcript 1 shuttled by prostate cancer cells-secreted exosomes initiates osteoblastic phenotypes in the bone metastatic microenvironment via miR-205-5p/runt-related transcription factor 2/splicing factor proline- and glutamine-rich/polypyrimidine tract-binding protein 2 axis [J]. Clin Transl Med，2021，11（8）：e493.
[28] Xin W，Zhao S，Han X，et al. lncRNA LA16c313D11.11 modulates the development of endometrial cancer by binding to and inhibiting microRNA2055p function and indirectly increasing PTEN activity [J]. Int J Oncol，2020， 57（1）：355-363.
[29] Makker A，Goel MM. Tumor progression，metastasis，and modulators of epithelial-mesenchymal transition in endometrioid endometrial carcinoma：an update [J]. Endocr Relat Cancer，2016，23（2）：R85-R111.
[30] Chen H，Fan Y，Xu W，et al. Exploration of miR-1202 and miR-196a in human endometrial cancer based on high throughout gene screening analysis [J]. Oncol Rep，2017，37（6）：3493-3501.
[31] 周进，付林，周珍，等.重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白递减联合沙利度胺递增治疗方案干预活动性强直性脊柱炎的1年评价[J].中国组织工程研究，2019，23（35）：5664-5669.
[32] Jia HL，Zhou DS. Down regulation of microRNA-367 promotes osteoblasts growth and proliferation of mice during fracture by activating the PANX3-mediated Wnt/β-catenin pathway [J]. J Cell Biochem，2019，120（5）：8247-8258. |
|
|
|
